$1.13
-0.08 (-6.61%)
Open$1.13
Previous Close$1.21
Day High$1.16
Day Low$1.06
52W High$6.23
52W Low$1.00
Volume—
Avg Volume517.8K
Market Cap12.20M
P/E Ratio—
EPS$-3.66
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,513.3% upside
Current
$1.13
$1.13
Target
$40.83
$40.83
$24.77
$40.83 avg
$47.84
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 731.2K | 1.39M | 2.02M |
| Net Income | -50,633,266 | -86,618,398 | 234.8K |
| Profit Margin | -6,925.2% | -6,578.9% | 11.6% |
| EBITDA | -56,022,445 | -101,161,989 | 368.8K |
| Free Cash Flow | — | — | 168.2K |
| Rev Growth | -47.4% | -47.4% | +14.4% |
| Debt/Equity | 0.33 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |